JOSD2 attenuates the aggressive behavior of fibroblast-like synoviocytes in rheumatoid arthritis by deubiquitinating and stabilizing ZNF148.
Increased JOSD2 attenuates the aggressive behaviors of RA-FLS and alleviates synovial inflammation, and the JOSD2-ZNF148 axis may represent a potential therapeutic strategy for RA.